Oyeka_2021_Cureus_13_e15641

Reference

Title : Progressive Supranuclear Palsy: Improvement in Cognitive-Behavioral Disturbances and Motor-Function Disabilities Following Treatment With Antidepressants and Cholinesterase Inhibitors - Oyeka_2021_Cureus_13_e15641
Author(s) : Oyeka M , Ibilah T , Israel J , Gavito-Higuera J , Salazar R
Ref : Cureus , 13 :e15641 , 2021
Abstract :

Progressive supranuclear palsy (PSP) is a neurodegenerative disease that usually develops after the sixth decade of life, and the diagnosis is purely clinical except in cases of pathologically confirmed autopsies. A multidisciplinary approach to meet the patients' complex needs is the current core treatment strategy for this devastating disorder. No medications can reverse the disease course. In this report, we present a case of PSP that developed after the sixth decade of life and where the diagnosis was supported by clinical and neuroimaging data. Despite the fact that PSP is a rapidly progressive neurodegenerative disorder and no effective treatments are currently available, our case illustrates the clinically significant improvement in cognition and function achieved in a patient with a treatment involving a combination of antidepressant medications and rivastigmine.

PubMedSearch : Oyeka_2021_Cureus_13_e15641
PubMedID: 34306851

Related information

Citations formats

Oyeka M, Ibilah T, Israel J, Gavito-Higuera J, Salazar R (2021)
Progressive Supranuclear Palsy: Improvement in Cognitive-Behavioral Disturbances and Motor-Function Disabilities Following Treatment With Antidepressants and Cholinesterase Inhibitors
Cureus 13 :e15641

Oyeka M, Ibilah T, Israel J, Gavito-Higuera J, Salazar R (2021)
Cureus 13 :e15641